Gilead Sciences (GILD.O), the maker behind the COVID-19 vaccine candidate Remdesivir is aiming for wider distribution – focusing on making the drug accessible and affordable for people. Daniel O’Day, Chief Executive of Gilead is planning to mass-produce the drug once it was approved.
Remdesivir (GS-5734) is one of the many candidates for coronavirus disease. Remdesivir is a broad-spectrum antiviral medication that was given by injection into a vein. Gilead’s recent press release announces results from its Phase 3 Trial of investigation using Remdesivir to cure severe COVID-19 patients.
“I can assure you that we’re all focused on making sure that we make this accessible and affordable to patients around the globe,” said O’Day.
According to Gilead Sciences, the study demonstrated that patients receiving a 10-day treatment course of Remdesivir achieved similar improvement in clinical status compared with those taking a 5-day treatment course.
Remdesivir is not yet licensed or approved anywhere globally and has not yet been demonstrated to be safe or effective for the treatment of COVID-19 but he assures that they are collaborating with the U.S. Food and Drug Administration for faster operation.
“We’re moving very quickly with the FDA,” added O’Day.
Though Gilead’s shares deflated to about 5.6% in early trading, the company’s stock rises to up to 30%.
More About Remdesivir
Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity both in vitro and in vivo in animal models against multiple emerging viral pathogens, including Ebola, Marburg, MERS and SARS. In vitro testing conducted by Gilead has demonstrated that Remdesivir is active against the virus that causes COVID-19. The safety and efficacy of Remdesivir for the treatment of COVID-19 are being evaluated in multiple ongoing Phase 3 clinical trials